Does Aetna (CVS Health) Cover Rezdiffra (Resmetirom)?

Aetna's Current Coverage Policy for Rezdiffra

Aetna classifies Rezdiffra (resmetirom) as a covered specialty medication for adults diagnosed with MASH and moderate-to-advanced hepatic fibrosis. The drug carries strict prior authorization requirements tied to clinical documentation. This is not a simple formulary drug you can pick up with a standard prescription.

Rezdiffra earned FDA accelerated approval in March 2024 as the first therapy specifically indicated for noncirrhotic MASH with moderate-to-advanced fibrosis (stages F2 and F3). That accelerated pathway matters for insurers. Aetna, like most large commercial payers, built its coverage criteria around the FDA label and the key trial data from MAESTRO-NASH. Coverage typically applies to Aetna's commercial PPO and HMO lines of business. Medicare Advantage and Medicaid managed-care plans administered by Aetna may have separate, more restrictive criteria or may not yet include Rezdiffra on their formularies.

Patients on employer-sponsored Aetna plans should confirm whether their specific plan document includes specialty pharmacy coverage for hepatology drugs, as self-funded employer plans can carve out categories at the employer's discretion.

Prior Authorization Criteria: What Aetna Requires

The PA process for Rezdiffra on Aetna is rated moderate-to-high difficulty. Your prescribing hepatologist or gastroenterologist will need to submit specific clinical evidence. Incomplete submissions are the most common reason for initial denials.

Aetna's prior authorization criteria generally require the following documentation: a confirmed diagnosis of MASH (previously called NASH) based on liver biopsy or validated noninvasive testing, evidence of hepatic fibrosis at stage F2 or F3 per the AASLD practice guidance on noninvasive assessment, the patient's age (18 years or older), and documentation that the prescriber is a hepatologist, gastroenterologist, or physician with documented expertise in liver disease management.

Fibrosis staging documentation is the make-or-break element. Aetna accepts liver biopsy results showing fibrosis stage F2 or F3 on the NASH CRN scoring system. Some plans also accept noninvasive assessments. A FibroScan (vibration-controlled transient elastography) result between 8.0 and 13.9 kPa generally corresponds to F2-F3 fibrosis. The Enhanced Liver Fibrosis (ELF) test score above 9.8 and FIB-4 index above 2.67 may also support the application, though biopsy remains the strongest evidence for a PA submission.

Lab values that strengthen the application include elevated ALT (typically above 1.5 times the upper limit of normal), along with imaging evidence of hepatic steatosis. The prescriber should include recent labs drawn within 90 days of submission. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg produced a 26% rate of MASH resolution with no worsening of fibrosis at 52 weeks compared to 10% with placebo [1]. Including this trial reference in a letter of medical necessity can help justify clinical need.

Step Therapy: What You Must Try First

Aetna requires step therapy before approving Rezdiffra. This means the patient must demonstrate an adequate trial of first-line interventions, or document a valid clinical reason why those interventions failed or are contraindicated.

The step therapy requirements typically include documented lifestyle modifications (dietary changes targeting weight loss of 7-10% of body weight and structured exercise) sustained for at least 6 months, along with consideration of off-label pharmacotherapy. Some Aetna plan documents reference vitamin E (800 IU daily for non-diabetic patients) or pioglitazone (30-45 mg for diabetic patients with MASH) as agents the patient should have trialed. The AASLD/AGA practice guidance notes that vitamin E at 800 IU daily improved steatohepatitis in the PIVENS trial (N=247), though it did not produce significant fibrosis improvement [2].

If the patient has a contraindication to vitamin E (such as history of prostate cancer or hemorrhagic stroke) or pioglitazone (such as heart failure, bladder cancer history, or osteoporosis risk), the prescriber should document these contraindications explicitly on the PA form. A clinical rationale explaining why the patient cannot safely complete step therapy often satisfies Aetna's requirement without the full trial period.

Patients with rapidly progressing fibrosis documented on serial elastography measurements 6 to 12 months apart may also qualify for a step therapy exception. The key is clinical urgency, and the documentation must tell that story clearly.

Formulary Tier and Out-of-Pocket Costs

Rezdiffra sits on specialty tier (Tier 4 or Tier 5) across most Aetna commercial formularies. Specialty tier placement means higher cost-sharing and mandatory use of a designated specialty pharmacy, which for Aetna is typically CVS Specialty.

The manufacturer list price for Rezdiffra is approximately $3,500 per month ($42,000 annually). Actual out-of-pocket costs depend on the plan's benefit design. For plans with coinsurance-based specialty tiers, patients commonly face 25-33% coinsurance, which translates to roughly $875 to $1,155 per month before any assistance programs. Plans with copay-based specialty tiers may cap the monthly cost at $150 to $500 depending on the employer's benefit structure.

Annual out-of-pocket maximums provide a ceiling. Under ACA-compliant plans, the 2026 out-of-pocket maximum for an individual is $9,450. Once a patient hits that threshold, the plan covers 100% of remaining costs for the calendar year. For patients on high-cost specialty medications like Rezdiffra, reaching the out-of-pocket maximum within the first 3-4 months of the year is common, which means the remaining months carry zero cost-sharing.

Madrigal Pharmaceuticals offers a manufacturer savings card (copay assistance program) for commercially insured patients. The program can reduce out-of-pocket costs to as little as $0 per month for eligible patients, with a maximum annual benefit that varies by program terms. Patients covered by government-funded insurance (Medicare, Medicaid, TRICARE) are not eligible for copay cards under federal anti-kickback rules. The FDA-approved prescribing information and the Madrigal patient support website provide enrollment details.

How to Appeal an Aetna Denial for Rezdiffra

Denials happen. Roughly 40-50% of initial specialty drug PAs are denied across the industry, according to AMA survey data on prior authorization. A denial is not the end of the process.

Aetna provides a structured two-stage appeal pathway. The first-level internal appeal must be filed within 180 days of the denial notice. The prescriber should submit a detailed letter of medical necessity that addresses each specific reason listed in the denial letter. Common denial reasons include insufficient documentation of fibrosis staging, incomplete step therapy documentation, or the prescriber lacking hepatology/GI specialization.

For the letter of medical necessity, include the patient's biopsy or elastography results with dates, a timeline of prior treatments attempted and their outcomes, relevant lab trends (ALT, AST, platelet count, FIB-4 trajectory), current BMI and metabolic comorbidities, and citations from the MAESTRO-NASH trial demonstrating the drug's efficacy in the patient's specific fibrosis stage [1]. Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH program, noted at AASLD's The Liver Meeting 2023 that "resmetirom is the first drug to show both MASH resolution and fibrosis improvement in a registrational trial, addressing an unmet need for patients progressing toward cirrhosis."

If the internal appeal is denied, patients have the right to an independent external review. This review is conducted by a third-party organization not affiliated with Aetna. External reviews are binding on the insurer in most states. The external review request must be filed within 4 months of the internal appeal denial in most jurisdictions. State insurance department websites list specific timelines and filing procedures.

During the appeal process, patients can request an expedited (urgent) review if the prescriber certifies that delay would seriously jeopardize the patient's health. For patients with F3 fibrosis at risk of progressing to cirrhosis, an expedited review is clinically justified.

Clinical Evidence Supporting Coverage

Aetna's coverage criteria are anchored to the MAESTRO-NASH trial data that supported FDA approval. Understanding this trial helps patients and prescribers frame PA submissions and appeals around the evidence Aetna's medical directors will review.

The MAESTRO-NASH phase 3 trial randomized 966 adults with biopsy-confirmed MASH and fibrosis (stages F1B through F3) to resmetirom 80 mg, resmetirom 100 mg, or placebo. At 52 weeks, 26% of patients on the 100 mg dose achieved MASH resolution with no worsening of fibrosis, compared to 10% on placebo (P<0.001). For the fibrosis-improvement endpoint, 26% of the 100 mg group achieved at least one stage of fibrosis reduction with no worsening of NASH activity score, compared to 14% on placebo (P<0.001) [1].

Resmetirom works as a thyroid hormone receptor-beta (THR-beta) selective agonist. It targets liver-specific pathways involved in lipid metabolism and fibrogenesis without the cardiac effects associated with non-selective thyroid hormone activation. In MAESTRO-NASH, LDL cholesterol dropped by approximately 16% in the 100 mg group at 24 weeks, an effect that may carry independent cardiovascular benefit for MASH patients who frequently have dyslipidemia [1].

The AASLD 2023 practice guidance on MASLD/MASH management references resmetirom as an FDA-approved treatment option for MASH patients with F2-F3 fibrosis [3]. The Endocrine Society's 2024 clinical guidance also acknowledges resmetirom's role in metabolic liver disease, particularly for patients with concurrent thyroid-metabolic dysfunction. These guideline citations carry significant weight in appeal letters.

Navigating CVS Specialty Pharmacy Requirements

Because Aetna is part of CVS Health, Rezdiffra prescriptions are typically routed through CVS Specialty pharmacy. This integration creates both advantages and specific requirements patients should anticipate.

CVS Specialty assigns each patient a dedicated care team, including a specialty pharmacist who monitors adherence, manages refill timing, and coordinates with the prescriber on lab monitoring. Resmetirom requires baseline and periodic thyroid function testing (TSH and free T4), as the drug's mechanism of action involves thyroid hormone receptor activation in the liver [4]. CVS Specialty may flag refill holds if updated lab results are not on file.

Patients should expect the first fill to take 5-10 business days after PA approval, as CVS Specialty verifies insurance coverage, applies copay assistance, and ships via cold-chain or specialty packaging as required. Subsequent refills follow a 30-day cycle with proactive outreach from CVS Specialty approximately 7 days before the ship date. Patients who prefer a different specialty pharmacy should confirm with Aetna member services whether their plan allows out-of-network specialty pharmacy dispensing, as many Aetna plans restrict specialty medications to CVS Specialty exclusively.

Tips for Getting Rezdiffra Approved on Aetna

A clean PA submission the first time saves weeks. The prescriber's office should gather all documentation before submitting: recent liver biopsy report or FibroScan results (within 12 months), lab panel including ALT, AST, platelet count, lipid panel, HbA1c, TSH, and free T4, documentation of 6+ months of lifestyle intervention, records of any prior MASH-directed pharmacotherapy trials, and a letter of medical necessity referencing the FDA-approved indication and MAESTRO-NASH efficacy data.

"Insurance coverage for the first FDA-approved MASH therapy has been a learning curve for payers and providers alike," stated Dr. Zobair Younossi, a hepatologist and health outcomes researcher at Inova Health System, in a presentation at AASLD 2024. "The key is matching patient documentation precisely to the FDA label and trial inclusion criteria."

Many hepatology practices now employ prior authorization coordinators or use electronic PA platforms (such as CoverMyMeds or SureScripts) that pre-populate Aetna's required fields. Ask your prescriber's office whether they use an electronic PA system, as these typically result in faster turnaround (48-72 hours versus 2-3 weeks for fax-based submissions).

Resmetirom is dosed at 80 mg daily for patients weighing <100 kg and 100 mg daily for patients weighing 100 kg or more [4]. Ensure the PA specifies the correct weight-based dose, as a mismatch between the patient's documented weight and the requested dose strength can trigger an administrative denial.